• Phase III plan laid out.

  • Our lead drug candidate cobitolimod has a new and unique mechanism of action to effectively and safely treat ulcerative colitis.

  • InDex Pharmaceuticals is developing treatments to increase the quality of life of patients suffering from immunological disorders.

  • InDex Pharmaceuticals hosted a virtual R&D day on December 8, 2020

Interim Report Q3 2020

InDex Pharmaceuticals Holding AB (publ) published its interim report for January-September 2020 on November 25 2020 at 08:00 a.m. CET.


The Share